12 resultados para pharmaceuticals in wastewater

em Cambridge University Engineering Department Publications Database


Relevância:

100.00% 100.00%

Publicador:

Relevância:

80.00% 80.00%

Publicador:

Relevância:

40.00% 40.00%

Publicador:

Resumo:

There is potential to extract energy from wastewater in a number of ways, including: kinetic energy using micro-hydro systems, chemical energy through the incineration of sludge, biomass energy from the biogas produced after anaerobic sludge digestion, and thermal energy as heat. This paper considers the last option and asks how much heat could be recovered under UK climatic conditions and can this heat be used effectively by wastewater treatment plants to reduce their carbon footprint? Four wastewater treatment sites in southern England are investigated and the available heat that can be recovered at those sites is quantified. Issues relating to the environmental, economic and practical constraints on how energy can be realistically recovered and utilised are discussed .The results show there is a definite possibility for thermal energy recovery with potential savings at some sites of up to 35,000 tonnes of total long-cycle carbon equivalent (fossil fuel) emissions per year being achievable. The paper also shows that the financial feasibility of three options for using the heat (either for district heating, sludge drying or thermophilic heating in sludge digestion processes) is highly dependant upon the current shadow price of carbon. Without the inclusion of the cost of carbon, the financial feasibility is significantly limited. An environmental constraint for the allowable discharge temperature of effluent after heat-extraction was found to be the major limitation to the amount of energy available for recovery. The paper establishes the true potential of thermal energy recovery from wastewater in English conditions and the economic feasibility of reducing the carbon footprint of wastewater treatment operations using this approach.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

The Pharma(ceuticals) industry is at a cross-roads. There are growing concerns that illegitimate products are penetrating the supply chain. There are proposals in many countries to apply RFID and other traceability technologies to solve this problem. However there are several trade-offs and one of the most crucial is between data visibility and confidentiality. In this paper, we use the TrakChain assessment framework tools to study the US Pharma supply chain and to compare candidate solutions to achieve traceability data security: Point-of-Dispense Authentication, Network-based electronic Pedigree, and Document-based electronic Pedigree. We also propose extensions to a supply chain authorization language that is able to capture expressive data sharing conditions considered necessary by the industry's trading partners. © 2013 IEEE.